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Exposure to arsenic-contaminated drinking
water represents one of the largest public
health poisonings in history, affecting tens of
millions of people worldwide (Chowdhury
2004). Bangladesh is one of the most
severely affected regions. Adverse health
effects associated with chronic exposure to
As-contaminated water include skin, blad-
der, kidney, and liver cancers, diabetes, and
hypertension [National Research Council
(NRC) 1999]. Reports in the literature sug-
gest that inorganic As (InAs) also poses
increased reproductive and developmental
risks in animals, though few human studies
have focused on these outcomes (DeSesso
et al. 1998; Waalkes et al. 2004). Relatively
little is known about transplacental transfer
of As. Several studies have addressed the
impact of human prenatal As exposure, and
have reported increases in miscarriage, still-
births, and congenital heart disease (Ahmad
et al. 2001; Borzsonyi et al. 1992;
Hopenhayn-Rich et al. 2000).
The As in drinking water is typically
inorganic, and can be present either as As+3
(arsenite) or As+5 (arsenate). In Bangladesh,
As is primarily in the As+3 form, though
there are reports of a signiﬁcant +5 fraction
in other parts of the Bengal Delta (Zheng
et al. 2004). The metabolism of As in
humans involves a series of reactions that
alternates reduction of pentavalent As
species to the trivalent state with oxidative
methylation steps (Vahter and Concha
2001). In humans this process results in dis-
tinct As species, including As+3
, As+5,
monomethylarsonous acid (MMA+3),
monomethylarsonic acid (MMA+5) and
dimethlyarsinic acid (DMA+5), each with
unique toxicology (Aposhian et al. 2004).
The trivalent As forms, which have a higher
afﬁnity for thiol groups (Vahter and Concha
2001), are more cytoxic and genotoxic than
pentavalent forms. Individuals who accu-
mulate the trivalent intermediates are
thought to be at greater risk of As-induced
diseases (Rossman et al. 2004; Thomas et al.
2004). A series of studies from Taiwan indi-
cate that individuals who excrete relatively
lower proportions of urinary DMA(+3) + (+5)
are at increased risk for skin and bladder
cancers and for peripheral vascular disease
(Chen et al. 2003a, 2003b; Hsueh et al.
1997; Tseng et al. 2005; Yu et al. 2000).
Interindividual differences in metabo-
lism of As are thought to account for some
of the observed variation in susceptibility to
As-related diseases (NRC 1999; Vahter
2000). Low body mass index (Milton et al.
2004) and reduced methylation capacity
(Davis and Uthus 2004; Gamble et al.
2005b) are thought to impair As metabo-
lism and enhance toxicity. Arsenic is methy-
lated by S-adenosylmethionine (SAM) via
one-carbon metabolism, a biochemical
pathway that uses folate for recruitment of
methyl groups and cobalamin (B12) as a
cofactor. We previously reported a high
prevalence of hyperhomocysteinemia in
Bangladesh that was found to be associated
with reduced As methylation (Gamble et al.
2005a, 2005b). We also found that As
methylation can be increased with folic acid
supplementation (Gamble et al. 2006.)
Early manifestations of arsenicosis, such
as skin lesions, occur in adults after many
years of exposure, whereas As-induced can-
cers and cardiovascular disease take decades
to develop. Little is known about the com-
parable latency periods in children.
Anecdotally, we have observed As-induced
skin lesions in preschool-age children in
Bangladesh, and have become concerned for
children who are now being born to a gen-
eration of mothers who have been exposed
to As for much or all of their lives. In addi-
tion, we recently reported that young chil-
dren exposed to As in drinking water exhibit
dose-dependent intellectual impairment
(Wasserman et al. 2004). These observations
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BACKGROUND: In Bangladesh, tens of millions of people have been consuming waterborne
arsenic for decades. The extent to which As is transported to the fetus during pregnancy has not
been well characterized.
OBJECTIVES: We therefore conducted a study of 101 pregnant women who gave birth in Matlab,
Bangladesh.
METHODS: Maternal and cord blood pairs were collected and concentrations of total As were ana-
lyzed for 101 pairs, and As metabolites for 30 pairs. Maternal urinary As metabolites and plasma
folate, cobalamin, and homocysteine levels in maternal cord pairs were also measured. Household
tube well–water As concentrations exceeded the World Health Organization guideline of 10 µg/L
in 38% of the cases.
RESULTS: We observed strong associations between maternal and cord blood concentrations of
total As (r = 0.93, p < 0.0001). Maternal and cord blood arsenic metabolites (n = 30) were also
strongly correlated: in dimethylarsinate (DMA) (r = 0.94, p < 0.0001), monomethylarsonate (r =
0.80, p < 0.0001), arsenite (As+3) (r = 0.80, p < 0.0001), and arsenate (As+5)( r = 0.89, p <
0.0001). Maternal homocysteine was a strong predictor of %DMA in maternal urine, maternal
blood, and cord blood (β = –6.2, p < 0.02; β = –10.9, p < 0.04; and β = –13.7, p < 0.04, respec-
tively). Maternal folate was inversely associated with maternal blood As5+ (β = 0.56, p < 0.05), and
maternal cobalamin was inversely associated with cord blood As5+ (β = –1.2, p < 0.01).
CONCLUSIONS: We conclude that exposure to all metabolites of inorganic As occurs in the 
prenatal period.
KEY WORDS: arsenic, B12, blood arsenic metabolites, DMA, folate, homocysteine, maternal,
MMA, newborn. Environ Health Perspect 115:1503–1509 (2007). doi:10.1289/ehp.9906 available
via http://dx.doi.org/ [Online 28 June 2007]strongly suggest that As exposure in utero
and/or during early childhood may be con-
tributing to As-induced health effects in chil-
dren. To determine the early health effects
associated with As, prenatal exposures must
be better characterized. The purpose of this
study was to characterize the As metabolic
proﬁles in maternal–cord blood pairs, and to
determine the extent to which maternal
folate and B12 status inﬂuences maternal As
metabolism. Here we report total blood As,
urinary As metabolites, folate, B12, and
homocysteine ﬁndings in 101 maternal–cord
blood pairs derived from births in Matlab,
Bangladesh, an area with a high prevalence
of elevated As concentrations in tube-well
water. We also describe blood As metabolites
in the 30 maternal–cord pairs that had the
highest total blood As.
Methods
Study participants. This study was approved
by the Institutional Review Board of the
Columbia University Medical Center and
the Ethical Review Committee of the
International Centre for Diarrheal Disease
Research-Bangladesh (ICDDR-B). Between
December 2004 and April 2005, pregnant
women who appeared at the main hospital in
Matlab, Bangladesh, were asked to partici-
pate in the study by the attending physican.
For the past 30 years, ICDDR-B has carried
out a disease surveillance program in Matlab,
an area that is roughly 20 km north of
Araihazar. Matlab is a region that has vari-
able concentrations of As in groundwater,
and where relatively little As remediation had
been carried out at the time of the study.
Through the efforts of ICDDR-B, roughly
half of all women in Matlab now deliver
their babies in the main hospital or in one of
several medical ﬁeld stations in the region.
A convenience sample of 104 pregnant
women participated in the study, all of
whom signed written informed consent.
This group is not necessarily representative
of all women in the study region. The pro-
ject benefited from the ICDDR-B health
and demographic surveillance system
(HDSS) in Matlab. HDSS records all vital
events, such as births, deaths, marriages,
including the date of the last menstrual
period, pregnancies, and pregnancy out-
comes, as well as in- and out-migration.
During their pregnancies, all women were
provided with daily iron (60 mg/day) and
folic acid (300 µg/day) supplements.
Sample collection and storage. Near the
time of delivery, women were asked to pro-
vide written informed consent, to answer a
brief questionnaire, to provide a blood and
urine sample before delivery, and to allow a
blood sample to be obtained from the
discarded umbilical cord after the birth of
the baby. The maternal and cord blood sam-
ples were typically taken within 1–2 hr of
each other. The questionnaire was adminis-
tered by a trained nurse, who also obtained
the blood and urine samples. The length
and weight of the baby at birth were also
recorded. In three cases, cord blood was not
collected; we therefore report on a sample
size of 101.
Blood samples were processed and frozen
at –80°C immediately in the hospital labora-
tory. Samples were collected in EDTA vacu-
tainers; serum was immediately separated for
folate, B12, and homocysteine analyses.
Urine samples were also collected in acid-
washed tubes and frozen at –80°C immedi-
ately. All samples were ultimately shipped on
dry ice to the Mailman School of Public
Health at Columbia University, and ana-
lyzed in the Trace Metals Core Laboratory;
shipment required approximately 36 hr.
Water As analyses. A tube well water
sample was obtained from 100 of the 101
women’s primary well shortly after delivery,
usually within a day, into 60-mL acid-
cleaned polyethylene bottles. These were
shipped to Columbia University’s Lamont
Doherty Earth Observatory where they were
acidified before analysis. Analytical proce-
dures have previously been described in
detail (Cheng et al. 2004). For the present
study, all water samples were analyzed using
an axiom single-collector high-resolution
inductively-coupled plasma mass spectrome-
ter (HR ICP-MS) (Thermo Elemental,
Erlanger, Germany). The analytical detec-
tion limit of the method is 0.1 µg As/L; the
standard deviation of a single measurement
is conservatively estimated at 4 µg/L for
concentrations up to 150 µg/L and 2% for
samples > 150 µg/L (van Geen et al. 2005).
Total As measurements. Urinary As con-
centrations were assayed by graphite furnace
atomic absorption spectrophotometry
(GFAA) using a PerkinElmer AAnalyst 600
system (PerkinElmer, Shelton, CT, USA) as
described (Nixon et al. 1991). Our laboratory
participates in a quality control program
coordinated by P. Weber at the Quebec
Toxicology Center, Quebec City, Quebec,
Canada. During the course of this study,
intraclass correlation coefﬁcients between our
laboratory’s values and samples calibrated at
Weber’s laboratory were 0.99. The detection
limit of the method is 2 µg/L. Urinary As lev-
els were also adjusted for urinary creatinine
concentrations, which were determined by a
standard colorimetric method based on Jaffe’s
reaction (Slot 1965), with reagents from
Sigma Diagnostics (Sigma Chemical
Company, St. Louis, MO, USA).
Maternal and cord venous whole blood
samples were analyzed for total blood As
concentration using a Perkin-Elmer Elan
DRC II ICP-MS equipped with an AS 93+
autosampler as described elsewhere (Hall
et al. 2006). Brieﬂy, the As concentration of
the standard solution used for instrument
calibration was chosen to cover the expected
range of As concentrations in the blood sam-
ples: 5, 25, and 50 µg/L. Matrix suppression
was compensated for by the use of iridium as
an internal standard, selected to match to the
ionization potential of As. Spectral interfer-
ences for As were resolved with dynamic
reaction cell (DRC) technology by introduc-
ing oxygen as a second gas. The intraclass
correlation coefficients between our labora-
tory’s values and samples calibrated at
Weber’s laboratory were 0.99. The detection
limit of the method is 0.06 µg/L.
As metabolite measurements. Urinary As
and blood As metabolites were separated by
high performance liquid chromatography
(HPLC), with a PerkinElmer HPLC Series
200 (PerkinElmer), and then quantified by
ICP-MS-DRC, using methods adapted from
Reuter and Neubauer (2003). Whole blood
specimens were digested using methods from
Csanaky et al. (2003). Frozen samples were
thawed and hemolyzed by mixing with 0.1
volume of 5.5% Triton X-100 in water.
Then, 0.1 volume of 150 mM aqueous mer-
cury chloride was added to displace trivalent
As from protein thiols. After these samples
were kept on ice for 1 min, they were depro-
teinized by mixing with one volume of 0.66
M ice cold HClO4 and centrifuged for
10 min at 4,000 rpm. The supernatant was
mixed with mobile phase buffer and injected
onto the HPLC column, connected to the
ICP-MS-DRC. Calibration standards of a
mixture of As metabolites were processed
similar to blood samples to achieve the same
pH and composition. Concentrations of cali-
bration standards were chosen to cover the
expected range of metabolite As concentra-
tions in blood samples.
Excellent separation by HPLC coupled
with very low detection limits of ICP-MS-
DRC allowed us to detect MMA, DMA,
As+3, and As+5, without online digestion of
organic forms, with great precision in blood
samples containing total As concentrations
≥ 10 µg/L. The peaks for arsenocholine (AsC)
and arsenobetaine (AsB), however, could not
be resolved at these low concentrations.
Therefore, we report the sum value for the
concentrations of AsC + AsB in blood. For
quality control we used two different types of
samples. We purchased blood samples with
known concentrations of 23 different elements
(including As) from the Institut de Sante
Publique du Quebec (Quebec, Canada), for
validation of ICP-MS analyses. We also cre-
ated our own set of blood specimens spiked
with five metabolites (AsC, As+3, DMA,
MMA, As+5) in three different concentrations
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ticipant samples; these were spiked at the
beginning of the study, aliquoted, and frozen.
We ran both sets of quality control samples at
the beginning of every working day and
throughout the day, after every 10 samples.
Interprecision during the course of this study
for AsC, As+3, DMA, MMA, and As+5 was
5.8, 7.0, 3.2, 4.5, and 9.6%, respectively.
To calculate the relative proportions of
InAs, MMA, and DMA, the amounts of
AsB and AsC were first subtracted from
total blood As values. Because the detection
limit of this method is 0.1 µg/L per individ-
ual metabolite (with a total dilution factor
of 22× for blood samples), metabolite data
was captured only on the 30 participants
with the highest As exposure—total blood
As > 10 µg/L.
Plasma folate, B12, and homocysteine. We
analyzed plasma concentrations of folate and
total cobalamin from maternal and cord
blood samples by radioimmunoassay
(Quantaphase II; Bio-Rad Laboratories,
Richmond, CA, USA) as described previ-
ously (Reuter and Neubauer 2003). The
within- and between-day coefﬁcients of vari-
ation for folate were 3% and 11%, respec-
tively, and those for cobalamin were 4% and
8%, respectively. Plasma homocysteine con-
centrations were measured by HPLC with
fluorescence detection according to the
method described by Pfeiffer et al. (1999).
The within- and between-day coefﬁcients of
variation for homocysteine were 5 and 8%,
respectively.
Statistical analyses. We calculated
descriptive statistics for sample characteristics
of mothers and their newborns. Scatterplots
were used to examine the relationships
between maternal and cord blood measures.
We tested bivariate correlations of variables
of interest based on estimated Spearman cor-
relation coefficients, and used paired t-tests
to detect mean difference between maternal
and cord measures or between maternal
blood and urine measures. We used multiple
linear regression analyses to determine
whether maternal folate and homocysteine
inﬂuence As metabolism, after adjusting for
potential confounding factors. The outcomes
variables, including maternal urinary As
metabolites (%DMA, %MMA, and %InAs),
maternal blood As metabolites, and cord
blood As metabolites (%DMA, %MMA,
%As+3, and % As+5) were regressed against
the main predictors variables, folate, B12, and
homocysteine, in separate models. Folate and
homocysteine data were log-transformed to
normalize their distributions. Control vari-
ables for analyses of maternal urinary
metabolites included maternal age, parity,
gestational age indicator (< 37 weeks vs. 
≥ 37 weeks), and log urinary creatinine.
Control variables for maternal blood As
metabolites were age and parity; for cord
blood As metabolites, adjustments were
made only for birth weight.
Results
Selected characteristics of the women and
their husbands and newborns are provided in
Table 1. Of note, on average, both the
mothers and fathers were reasonably well
educated, and 89% of the mothers could
read and write. There were no signiﬁcant dif-
ferences when these characteristics were com-
pared between the subset for whom blood As
metabolite data was obtained and the
remaining 71 women (data not shown).
Mean values of water As, urinary As, and
total blood As concentrations, as well as
plasma folate, B12, and homocysteine mea-
surements are summarized in Table 2. The
mean maternal tube well water As concen-
tration was 90.5 µg/L, with 28% of the
wells exceeding the Bangladesh standard of
50 µg/L, and 38% exceeding the World
Health Organization standard of 10 µg/L
(Chowdhury 2004). Water As was signifi-
cantly associated with both maternal and
cord total blood As (r = 0.40, p < 0.0001;
Arsenic metabolism in maternal–newborn pairs
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Table 1. Characteristics of the study sample (n = 101).
Variable Value Range
Mother’s age (years) 26.0 (5.3) 16.7–39.0
Father’s age [years (n = 63)] 34.4 (7.0) 21.7–52.7
Mother’s education (years) 7.4 (3.6) 0–14
Father’s education (years) 7.6 (4.6) 0–16
Mother’s height (cm) 150.1 (6.0) 134–164
Parity 1.8 (0.90) 1–4
Gestational age (days) 278.4 (16.6) 218–318
Placenta weight (g) 513.6 (120.5) 300–1,030
Birth weight (g) 2752.4 (456.4) 1,160–4,000
Birth length (cm) 47.9 (2.9) 32.6–54
Head circumference [cm (n =100)] 31.7 (2.5) 24.2–48.2
Male births 58 (57.4)
Female births 42 (42.6)
Married 101 (100)
Father’s occupation
Unemployed 5 (5.0)
Farmer/daily labor 24 (23.8)
Factory worker/other paid job 22 (21.8)
Business 21 (20.8)
Other 29 (28.7)
Mother able to read and write 90 (89.1)
Values are mean ± SD or no. (%). 
Table 2. Values for water, urine, and whole blood As and plasma folate, B12, and homocysteine measurements (n= 101).
Variable Value Range
Water As [µg/L (n = 100)]  90.5 ± 165.8 0.1–661.0
Cord blood 
As (µg/L) 15.7 ± 8.7 2.9–74.6
As [µg/L (n = 30)]a 23.1 ± 11.2 10.0–74.6
Hemoglobin (g/dL) 16.0 ± 1.6 10.8–19.4
Folate [nmol/L (n = 96)] 52.7 ± 16.7 24.8–106.3
Homocysteine [µmol/L (n = 100)] 5.7 ± 1.4 2.9–11.6
B12 [pmol/L (n = 91)] 370.4 ± 222.6 88.8–1321.1
Mother’s blood
As (µg/L) 11.9 ± 8.6 3.1–76.5
As [µg/L (n = 30)]a 20.0 ± 12.1 10.7–76.5
Hemoglobin (g/dL) 12.7 ± 1.4 8.7–15.9
Folate [nmol/L (n = 99)] 20.3 ± 9.9 6.2–42.2
Homocysteine (µmol/L) 6.4 ± 1.5 3.6–10.9
B12 [pmol/L (n = 95)] 180.8 ± 71.5 84.8–458.9
Folate < 6.8 (nmol/L) 1 (1.0)
Folate < 9 (nmol/L) 10 (10.1)
Homocysteine > 10.4 (µmol/L) 2 (1.9)
B12 < 185 56 (58.9)
Mother’s urine
As (µg/L) 127.6 ± 232.9 5.0–1384.0
Creatinine (mg/dL) 48.6 ± 35.3 8.6–178.9
As (µg/g creatinine) 271.7 ± 489.5 5.2–3084.4
pH (n = 100) 5.9 ± 0.7 5.0–7
Values are mean ± SD or no. (%).
an = 30 subset is comprised of participants with total blood As > 10 µg/L.and r = 0.35, p = 0.0003, respectively).
Water As was also significantly associated
with maternal urinary As (micrograms per
gram creatinine) (r = 0.52; p < 0.0001).
The mean cord total blood As values of
15.7 µg/L in the total sample (n = 101) and
23.13 mg/L in the subset (n = 30) exceeded
the mean maternal total blood As of 11.9
µg/L (n = 101) and 20.02 mg/L (n = 30) by
32% (p < 0.0001) and 16% (p < 0.0001),
respectively. This statistically signiﬁcant ﬁnd-
ing is likely attributable to the greater con-
centration of hemoglobin in cord blood. The
ranges for both of these parameters were
extremely wide, undoubtedly reflecting, in
part, the wide range of water As (Table 2).
The relative proportions of As+3, As+5,
MMA, and DMA were virtually identical in
terms of mean values in maternal and cord
blood (Table 3). In each case the mean pro-
portions were 43% DMA, 30% MMA, 13%
As3+, and 13% As5+. Compared with mater-
nal urine (Table 3), maternal blood con-
tained substantially higher proportions of
InAs (i.e., As+3 + As+5) and MMA but less
DMA. The spearman correlation coefﬁcient
between the sum of urinary As metabolites
and the sum of blood As metabolites is 0.88.
For maternal and cord blood As analy-
ses, we compared the total As concentration
with the sum of As metabolite concentration
values obtained by HPLC-ICP-MS. To do
so, we adjusted for the HPLC percent recov-
ery. The same approach was used to com-
pare total urine As concentrations obtained
by GFAA to those derived from the sum of
urinary As metabolites via HPLC-ICP-MS.
Recoveries for the HPLC-ICP-MS methods
were 57% for cord blood (n = 30), 69% for
maternal blood (n = 30), and 89% for
maternal urine (n = 101). Comparison of
the recovered-adjusted sum of As metabolite
concentrations with the measured total As
concentrations, for cord blood, maternal
blood, and maternal urine, shows good
agreement (Table 3) with concordance cor-
relation coefﬁcient of 0.87, 0.91, and 0.99,
respectively.
The mean cord plasma folate and B12
values (52.7 nmol/L and 370.4 pmol/L,
respectively) were more than twice those in
maternal blood (p < 0.0001), whereas cord
plasma homocysteine was 11% lower than
maternal plasma homocysteine (p < 0.0001)
(Table 2). Inadequate plasma folate during
pregnancy, defined here as < 6.8 nmol/L
(Tamura and Picciano 2006), was found in
1% of the study participants. Vitamin B12
deficiency, defined here as < 185 pmol/L
based on nonpregnant reference values pre-
viously reported (Christenson et al. 1985),
was found in 58.9% of the women in this
study (Guerra-Shinohara et al. 2002; B12
pregnancy-specific reference ranges are not
available). The prevalence of hyperhomo-
cysteinemia was low (1.9%), based on non-
pregnant cutoffs of > 10.4 µmol/L for
women from the Third National Health
and Nutrition Examination Survey. 
Table 4 summarizes the results from mul-
tiple linear regression analyses used to deter-
mine whether maternal plasma folate and
homocysteine concentrations influence As
metabolism. Maternal homocysteine was a
strong predictor of %DMA in maternal urine,
maternal blood, and cord blood (β = –6.2, 
p < 0.02; β = –10.9, p < 0.04; and β = –13.7,
p < 0.04, respectively). A positive association
was also found between maternal homocys-
teine and urinary InAs (β = 0.84, p < 0.009),
maternal blood As5+ (β = 1.3, p < 0.02), and
cord blood As5+ (β = 1.3, p < 0.04). Maternal
folate was inversely associated with maternal
blood As5+ (β = –0.56, p < 0.05), and mater-
nal B12 was inversely associated with cord
blood As5+ (β = –1.2, p < 0.01).
We used multiple linear regression
analyses to examine the predictors of mater-
nal total blood As. We hypothesized that
total blood As would decline with increasing
parity, because it is known that maternal
blood lead declines with parity due to the
gradual “shedding” of the maternal body
burden into each offspring. Because total
blood As and water As had skewed distribu-
tion, these variables were log-transformed.
Water As was positively associated with
maternal total blood As, controlling for par-
ity (β = 0.074, p < 0.0001). As hypothe-
sized, parity was inversely associated with
Hall et al.
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Table 3. Maternal and newborn blood As metabolites and maternal urinary As metabolites for participants with total
blood As > 10 µg/L (n = 30).
Variable Mean ± SD Range
Cord blood As metabolites
%DMA 43.1 ± 8.9 28.9–68.7
%MMA 31.1 ± 6.3 18.5–42.7
%As+3 12.8 ± 2.7 4.3–16.8
%As+5 12.9 ± 6.5 4.2–31.1
Sum of As metabolites(µg/L) 24.0 ± 15.3 5.4–83.5
Total blood As (µg/L) 23.1 ± 11.2 10.0–74.6
Mother’s blood As metabolites
%DMA 43.5 ± 8.0 32.7–66.9
%MMA 30.1 ± 5.7 18.4–39.2
%As+3 13.0 ± 2.9 4.5–18.0
%As+5 13.4 ± 6.3 2.4–34.5
Sum of As metabolitesa(µg/L) 20.9 ± 13.1 4.8–67.9
Total blood As (µg/L) 20.0 ± 12.1 10.9–76.6
Mother’s urine As metabolites
%DMA 86.6 ± 5.5 74.8–97.3
%MMA 7.6 ± 4.1 1.5–17.7
%InAs 5.9 ± 2.4 1.2–11.0
Sum of urinary As metabolitesa 717.5 ± 687.1 43.4–2934.6
(µg/g creatinine)
Total urinary As (µg/g creatinine) 726.0 ± 715.7 39.4–3084.2
aReported sum values have been corrected for percent recovery, as described in “Methods.” Urine and blood As metabo-
lites were measured by HPLC ICP-MS-DRC, whereas total urinary As and total blood As were measured by GFAA and
ICP-MS-DRC, respectively.
Table 4. Estimated regression coefﬁcients, β (SE) in models relating folate and homocysteine to maternal
urinary As metabolites and maternal and cord blood metabolites.
Main predictor variable
Outcome variable log (folate) log (homocysteine)
Maternal urinary metabolitesa,b(n = 99)
%DMA –0.6 (1.4) –6.2 (2.6)*
%MMA 1.1 (0.7) 1.4 (1.3)
%InAs –0.1 (0.2) 0.8 (0.3)*
Maternal blood metabolitesb,c (n = 29)
%DMA 3.5 (3.3) –10.9 (5.0)*
%MMA 1.2 (2.1) –2.1 (3.9)
%As+3 –0.3 (1.2) 3.5 (1.9)
%As+5 –0.6 (0.3)* 1.3 (0.5)*
Cord blood metabolitesb,d(n = 29)
%DMA 0.1 (4.8) –13.7 (6.2)*
%MMA 2.7 (3.7) 0.6 (5.0)
%As+3 0.7 (1.5) 3.8 (1.9)
%As+5 –0.4 (0.4) 1.3 (0.6)*
aModel was adjusted for the control variables maternal age (years), parity, indicator for gestational age (< 37 weeks vs.
≥ 37 weeks), and log (urinary creatinine). bUnadjusted values were similar to adjusted values. cModel was adjusted for
the control variables maternal age (years) and parity. dModel was adjusted for the control variable birth weight. *p < 0.05.maternal total blood As (r = -0.22, p =
0.025), but after adjustment for water As,
this association was only marginally signifi-
cant (p = 0.094). Parity was not associated
with cord total blood As before or after con-
trolling for maternal total blood As.
There was a strong association between
the maternal and cord total blood As con-
centrations (r = 0.84, β = 0.94, p < 0.0001)
(Figure 1). In the subset of 30 maternal–cord
blood pairs for which blood As metabolite
data were detectable, there were also strong
associations for each As metabolite, as
depicted in Figure 2. 
Discussion
The appearance of As in cord blood is
extremely troubling because gestation is a
period of high sensitivity to carcinogens
(Anderson et al. 2000). Waalkes and co-
workers (2004) have demonstrated that adult
mice that had been briefly exposed to As
during their own fetal development (during
gestation days 8–18) developed tumors of
the liver, ovary, adrenal gland, and lung, as
well as preneoplastic lesions of the uterus and
oviduct. Recently, the same group reported
that when pregnant mice were exposed to
As3+ in their drinking water, As3+ behaved as
a complete carcinogen in male offspring,
which subsequently developed liver, lung,
kidney, and adrenal gland tumors. In addi-
tion, when As3+ exposure was combined with
either in utero or postnatal estrogen, liver
lesions were enhanced and bladder lesions
also developed (Waalkes et al. 2006).
Relatively little research has examined
the extent to which As exposure in pregnant
women leads to exposure of the fetus to As.
Two previous reports examined As concen-
trations in maternal–cord blood pairs. A
1991 report described ﬁndings derived from
82 births from three cities in Taiwan (Soong
et al. 1991). Compared with the current
study, their total blood As concentrations
were low, with mean maternal and cord
blood levels of only 7 and 8 µg As/L, respec-
tively. In that low range, the authors
reported a correlation between maternal and
cord total blood As of 0.57 (p < 0.001). A
second study of 11 births in northern
Argentina also involved relatively low blood
As concentrations and found a comparable
association (Concha et al. 1998). Our pre-
sent study is unique in that the study popu-
lation had a very wide range of water As
exposures, it employed a more sensitive and
precise analytical method (i.e., ICP-MS-
DRC), and, in addition to total blood As, it
measured blood As metabolites, urinary As
metabolites, and plasma folate, B12, and
homocysteine concentrations. Across the
range of water As exposures in this study
population (0.1–661.0 µg/L), the correla-
tion between maternal and cord total blood
As was very strong (r = 0.84, p < 0.0001).
An additional concern regarding exposure
to As during the prenatal period is the possible
effects on birth outcomes. Hopenhayn et al.
(2003) studied 844 births in two towns in
Chile, one of which (Valparaiso) had water As
< 1 µg/L and the other (Antofagasta) had a
range of 33–53 µg/L. They reported that, after
controlling for covariates, the mean birth
weight in Antofagasta was 57 g lower that that
in the nonexposed group, but this difference
across towns did not achieve statistical signiﬁ-
cance. A much larger retrospective study of
18,259 firstborn singleton live births took
place in two rural regions of Taiwan which
had low and high (up to 3.59 mg/L) water As
concentrations (Yang et al. 2003). After con-
trolling for maternal age, marital status, mater-
nal education, and sex of the infant, Yang et al.
(2003) observed a significant difference in
birth weight of 29 g between exposed and
“nonexposed” regions (p = 0.002). However,
the ecologic nature of this study, and its use of
“extreme points of contrast” limit the ability to
make causal inferences.
An additional concern about transpla-
cental transfer of As and its metabolites dur-
ing the prenatal period relates to our recent
findings of a dose-dependent adverse rela-
tionship between As exposure and intelli-
gence in young. Two separate cross-sectional
studies of Bangladeshi children, one in
10-year-old children (Wasserman et al.
2004) and the second in 6-year-old children
Arsenic metabolism in maternal–newborn pairs
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Figure 1. Associations between cord and maternal blood arsenic for (A) total blood arsenic (n = 30, r = 0.97, β = 0.90, blue line; n = 101, r = 0.93, β = 0.94, black line)
and (B) the adjusted sum of blood arsenic metabolites (DMA + MMA + As+3 + As+5) (n = 30, r = 0.99, β = 1.16).
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A B(Wasserman et al. 2007), find deficits in
visual motor functioning associated with As
exposure. At this point it is unclear how
much of these deficits can be attributed to
prenatal as opposed to postnatal exposures.
Household well water As concentrations
obtained in the perinatal period proved to be
predictive of both maternal and cord blood
As, but these associations were considerably
weaker (r = 0.40 and 0.35, respectively) than
that with maternal urine As (r = 0.51). The
proportion of DMA excreted in maternal
urine (87%) was quite high compared with
that observed in our previous cross-sectional
study of men and nonpregnant women
(71%) (Gamble et al. 2005b). This may be
attributed partly to changes in As metabo-
lism during pregnancy (Hopenhayn et al.
2003) or to the fact that women in the cur-
rent study were supplemented with folic
acid, which enhances As methylation
(Gamble et al. 2006). 
We observed that compared with mater-
nal urine, maternal blood contained higher
proportions of MMA and InAs and lower
DMA. This ﬁnding is consistent with litera-
ture reports indicating that methylated As
species have shorter half-lives of elimination
than inorganic forms (Buchet et al. 1981;
Vahter and Concha 2001). The literature
concerning the proportions of various As
metabolites in human blood is scant, but our
ﬁndings are coherent with those of Pi et al.
(2002), who reportedly found the propor-
tions of InAs, MMA, and DMA to be 19.4,
49.2, and 31.4%, respectively, in adults. 
Although the utility of blood As as a bio-
marker of As exposure is only now being
established (Hall et al. 2006), our ﬁndings do
make it clear that maternal–fetal transport of
As readily occurs. Importantly, the strong
associations reported here between maternal
and cord blood As metabolites demonstrate
that the fetus is exposed to the full range of
As species generated during As metabolism,
although we cannot infer whether this occurs
through passive diffusion of As metabolites or
fetal metabolism of InAs.
Folate and homocysteine appear to be
important determinants of As methylation.
The importance of these parameters may be
heightened during pregnancy, due to the
increased demand for folate for fetal devel-
opment. Animal studies have shown that
insufﬁcient folate intake decreased InAs bio-
transformation and excretion, and increased
tissue retention and toxicity (Spiegelstein
et al. 2003; Vahter and Marafante 1987),
but until recently few human studies have
focused on the role of folate in As metabo-
lism. Folate deﬁciency during pregnancy has
been associated with various complications,
including placental abruption, preeclampsia,
and spontaneous abortion (George et al.
2002; Picciano 2003; Tamura and Picciano
2006), and it is well established that folic
acid supplementation prevents neural tube
defects and reduces the incidence of low
birth weight (NRC 1998). However, in
developing countries folate deficiency
among unsupplemented pregnant women is
still a public health concern (Tamura and
Picciano 2006). Studies to delineate more
fully the risks to pregnant women who are
both folate deﬁcient and exposed to InAs in
drinking water should be a high priority.
The low prevalence of folate deficiency
among these participants likely reflects the
fact that these women received folic acid
supplements during pregnancy. Our find-
ings are also consistent with previous reports
that blood folate concentrations of the new-
born are significantly higher than maternal
levels, presumably reflecting the in utero
active transport process (NRC 1998). Our
observation that fetal B12 concentrations
were more than twice those of maternal lev-
els is also in line with other reports (Molloy
et al. 2002; Obeid et al. 2005; Steegers-
Theunissen et al. 1997).
In summary, we have demonstrated
strong relationships between maternal and
cord total blood As and blood As metabolite
concentrations, which indicate that newborn
children in Matlab, and likely other regions
of Bangladesh, are exposed to hazardous con-
centrations of As metabolites during the pre-
natal period. Given the findings reported
here, we conclude that As metabolism may
be impaired and its toxicity heightened in
populations, such as in Bangladesh, where
foods are not folic acid enriched and prenatal
supplements are not always available.
Interestingly, homocysteine—even at levels
that are within the normal range and even
after folic acid supplementation—is associ-
ated with decreased As methylation. Efforts
to reduce As exposure should be a high pri-
ority, because this element has adverse effects
on early childhood development, is a well-
established carcinogen, and has potential
synergistic effects with other co-exposures.
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